Pure Encapsulations – owned by Nestlé – will now sell CBD soft gel formulations which use the patented VESIsorb drug delivery system for improved absorption and bioavailability.
The first large-scale production was completed and delivered earlier this month using only European resources, including cultivation and extraction of the hemp biomass in Slovenia and drug delivery technology and soft gel capsule production in Switzerland.
The first product that Pure Encapsulations is launching in Europe is a soft gel capsule with a science-backed two-to-one ratio of CBD (cannabidiol) to BCP (beta-caryophyllene) from broad spectrum hemp extract that utilises the VESIsorb delivery system.
“We are extremely proud to expand our relationship with Nestlé’s healthcare professional brands into Europe after their success in the U.S. market this past year,” said Jesse Lopez, CEO and founder of Geocann.
“Their leadership team’s validation of science-backed and clinically-proven hemp products is an important milestone for our industry and provides exceptional credibility to the therapeutic benefits of cannabinoids formulated with VESIsorb.”
Dr. Barry Ritz, Chief Science Officer at Pure Encapsulations, adds: “Our partnership is built on a relentless effort to ensure these are the most science-backed CBD products in the world, setting the benchmark for what consumers expect and healthcare professionals demand.”
The CBG soft gel products utilise the VESIsorb delivery system developed by Swiss company Vesifact, a spin-off of the Federal Institute of Technology in Zurich. The delivery system is described as a self-assembling colloidal droplet delivery system, and is covered by multiple patents.
Chicago-based SourceOne serves as the exclusive worldwide distribution and marketing partner for the technology. Lopez is also the CEO and founder of SourceOne Global Partners.
The VESIsorb technology was introduced to the US about 16 years ago, first with CoQ10, and then adapted the technology for other ingredients such as QH ubiquinol, resveratrol, and CBD.
A recent study in Molecules supported the efficacy of VESIsorb to enhance absorption and bioavailability of a CBD-hemp extract, compared to the same hemp extract diluted with medium-chain triglycerides.
“[The self-emulsifying drug delivery system]-CBD based on VESIsorb formulation technology offers a novel, good, tolerable, and effective oral cannabinoid delivery system,” wrote the study’s authors. “CBD has a number of potential health benefits, however, our data demonstrated that unless the SEDDS formulation is used, there is relatively poor bioavailability of the standard CBD formulations (e.g., Hemp-Extract diluted with MCT oil) and could lead to diminished benefits (or no benefit) for this natural product.”
Geocann has applied the VESIsorb technology to a wide range of product applications, including soft gel and hard capsules, functional foods (e.g. gummies), beverages, powder systems, tinctures, sublingual sprays, and topically applied formulations.